PonceauS staining was used to confirm even loading between groups.Twentyfourhafter infection, cells were Glumetinib treated with M CDDP or DMSO.At hafter infection, cells were treated with M CDDP or DMSO control.The cells were treated with M CDDP or DMSO hafter infection.Fortyeighthafter infection, cells were treated with M CDDP or DMSO.CDDP sensitivity of C cells was concentration dependent. Interestingly, at M, PFT increased overall cell death in all groups, indicative of nonspecific PFT toxicity; we subsequently determined the maximum tolerable dose of PFT to be M, and this concentration was used for all subsequent experiments.To confirm the functionality of the exogenous wildtype p, we determined p content.Although p content was undetectable in the absence of exogenous p, reintroduction of wildtype p increased p content in a dosedependent manner, an effect that was attenuated by the presence of PFT. However, the effects of PFT were reversed by overexpression of wildtype p. A, OV and C cells were cultured and treated with CDDP at increasing doses. One recent review has suggested that there is an approximately overall incidence of p mutation in epithelial ovarian cancer. Although CDDP induced a concentrationdependent increase in p in the chemosensitive OV cell line, p was not detectable in C cells at any of the CDDP doses. Xiap is also known to act as its own E ubiquitin ligase. Both p mutation and chemoresistance occur at extremely high frequencies in ovarian cancer.Click on Request Permissions which will take you to the Copyright Clearance Centers Downloaded from cancerres.aacrjournals.org on April. American Association for Cancer Research. ABT is a recently described inhibitor of members of this family.We investigated whether this compound could sensitize ovarian cancer cells to chemotherapeutic agents.However, ABT, but not a less active enantiomer, increased the sensitivity of several cell lines to carboplatin.The increased sensitivity to carboplatin was accompanied by a decrease in time at which apoptosis was observed when assessed according to the number of attached cells, PARP cleavage, and nucleosome formation.ABT was more effective at sensitizing IGROV cells when ABT was administered after carboplatin.In addition, ABT significantly enhanced the activity of carboplatin in one of three primary cultures derived directly from ascitic tumor cells in patients recently treated with chemotherapy.ABT was also able to augment the inhibition of IGROV tumor xenograft growth beyond that obtained with carboplatin alone.The currently most frequently used therapy for the treatment of ovarian cancer is a combination of carboplatin and paclitaxel.Although f of patients initially respond well to therapy, the majority of patients suffer recurrent disease. In some cases, patients respond well to repeated treatment with the same chemotherapeutic regimen but they will inevitably succumb to the disease following the eventual emergence of drug resistance.As a consequence, the overall year survival is only. Thus, there is a pressing need to either identify novel therapies for ovarian cancer or to discover drugs which sensitize tumor cells to existing chemotherapy.Indeed, it is possible that numerous resistance mechanisms could contribute to a drugresistant phenotype and these mechanisms might be coordinately regulated. BclXL expression in clinical samples has also been linked to the resistance of prostate cancer to androgen therapy.